New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR
April 21 2009 - 10:12AM
Business Wire
GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported
that pre-clinical data on RGB-286638, the Company�s multi-targeted
protein kinase inhibitor, are being presented at the American
Association for Cancer Research (AACR) 100th Annual Meeting in
Denver, Colorado. Researchers from the Dana-Farber Cancer Institute
and the Massachusetts General Hospital Cancer Center (MGH), Boston,
Massachusetts gave an oral presentation entitled, �A Novel
Multi-Targeted Small Molecule Inhibitor RGB-286638 Triggers
Apoptosis and Necrosis in Multiple Myeloma via Dual Cell Death
Pathways.� The data show that RGB-286638 demonstrates in vivo
activity in several pre-clinical models of multiple myeloma. The
compound also induces cell death in multiple myeloma cells
independent from the p53 status; p53 is a gene involved in the
control of cell proliferation.
�The data presented today by the MGH/Dana-Farber further support
the potential role of RGB-286638 in the treatment of multiple
myeloma,� said Bernd Seizinger, M.D., Ph.D., Chief Executive
Officer of GPC Biotech. �Based on these data, we are working with
the MGH/Dana-Farber team to design a Phase 1 clinical study in
patients with hematological tumors, including multiple
myeloma.�
Additionally, pre-clinical data on RGB-286638 in solid tumor
cell lines are being presented by GPC Biotech researchers in a
poster entitled, �RGB-286638, a multi-targeted protein kinase
inhibitor, induces apoptosis involving the inhibition of RNA
polymerase II carboxyl-terminal domain phosphorylation and the loss
of the anti-apoptotic BCL2 family member Mcl-1� (Abstract #3265).
These data demonstrate that RGB-286638 induces rapid tumor cell
killing at very low doses. Additionally, RGB-286638 shows a potent
profile of activities across a broad range of solid tumor cell
lines, including cell lines originated from prostate, pancreas and
kidney cancers. A Phase 1 trial evaluating RGB-286638 in patients
with advanced solid tumors is currently underway in Europe.
About RGB-286638
RGB-286638 is a multi-targeted protein kinase inhibitor
currently in Phase 1 clinical testing. The RGB-286638 compound has
been shown to inhibit the processes controlling cell division in
cancer cells by targeting multiple cyclin-dependent kinase proteins
involved in regulating the cell cycle. RGB-286638 has also been
shown to induce apoptosis (programmed cell death) and to inhibit
other important protein kinases involved in the proliferation of
cancer cells. RGB-286638 treatment results in tumor regression and
increased survival in a number of pre-clinical models of solid and
hematological tumors.
GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company
focused on developing anti-cancer drugs. The Company currently has
two programs in clinical development: satraplatin, an oral platinum
compound and RGB-286638, a multi-targeted protein kinase inhibitor.
On February 18, 2009 the Company announced plans to combine its
business with U.S.-based Agennix, Incorporated in a new German
company. Agennix, a privately-held biotechnology company, is
developing oral talactoferrin, a product candidate that is
currently in Phase 3 trials for non-small cell lung cancer. GPC
Biotech AG is headquartered in Martinsried/Munich (Germany) and has
a wholly owned U.S. subsidiary in Princeton, New Jersey. For
additional information, please visit GPC Biotech's Web site at
www.gpc-biotech.com.
This press release contains forward-looking statements, which
express the current beliefs and expectations of the management of
GPC Biotech. Such statements are based on current expectations and
are subject to risks and uncertainties, many of which are beyond
our control, that could cause future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a
number of factors, and we caution investors not to place undue
reliance on the forward-looking statements contained in this press
release. There can be no guarantee that RGB-286638 will be
successfully developed. Forward-looking statements speak only as of
the date on which they are made and GPC Biotech undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Historical Stock Chart
From Dec 2023 to Dec 2024
